A multi-cohort, randomized, Phase 2, open-label study to assess the preliminary efficacy, safety, and pharmacokinetics of BIVV020 for prevention and treatment of antibody-mediated rejection in adult kidney transplant recipients
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Riliprubart (Primary) ; Antithymocyte globulin; Corticosteroids; Immunoglobulins; Mycophenolate; Rituximab; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
- 09 Jan 2025 Planned End Date changed from 3 Dec 2026 to 17 Nov 2026.
- 09 Jan 2025 Planned primary completion date changed from 9 Dec 2025 to 27 Oct 2025.
- 09 Jan 2025 Status changed from recruiting to active, no longer recruiting.